GlassScriptPhysician profile
Todd V Panarese
NPI 1427125053
$9,583.03
in general payments reported to CMS, 2019-2025
59 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,479 · 2020: $581 · 2021: $1,495 · 2022: $763 · 2023: $1,329 · 2024: $1,791 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $778.08 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $601.37 | 2019-2025 | Rybrevant, Darzalex, Carvykti |
| Eisai INC. | $525.50 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $479.72 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $416.79 | 2020-2025 | |
| Incyte Corporation | $412.84 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $358.16 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $305.21 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $303.59 | 2019-2025 | |
| Seagen INC. | $299.20 | 2020-2023 | Tukysa, Padcev |
| Servier Pharmaceuticals LLC | $281.02 | 2022-2025 | |
| Astellas Pharma US INC | $280.09 | 2019-2025 | Vyloy, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $269.85 | 2021-2025 | Vonvendi, Fruzaqla, Alunbrig |
| Jazz Pharmaceuticals INC. | $261.42 | 2022-2025 | |
| Genentech USA, INC. | $255.24 | 2019-2025 | Venclexta, Alecensa, Tecentriq |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $207.00 | 2021-2025 | Provenge |
| Mirati Therapeutics, INC. | $162.83 | 2023-2024 | Krazati |
| Beigene USA, INC. | $155.35 | 2020-2025 | Brukinsa |
| Taiho Oncology, INC. | $152.95 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $152.47 | 2022-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $149.19 | 2019-2023 | Tazverik |
| Novocure INC. | $146.46 | 2019-2025 | Optune, Optune Gio |
| Abbvie INC. | $144.22 | 2022-2025 | |
| Glaxosmithkline, LLC. | $144.14 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Daiichi Sankyo INC. | $143.31 | 2024-2025 | Enhertu, Datroway |
| Celgene Corporation | $142.06 | 2019-2020 | |
| Blueprint Medicines Corporation | $135.00 | 2021 | |
| Tersera Therapeutics LLC | $134.70 | 2023-2025 | Zoladex |
| Genzyme Corporation | $131.08 | 2021 | |
| Exelixis INC. | $125.53 | 2021 | |
| Epizyme, INC. | $125.00 | 2020 | |
| Eusa Pharma (US) LLC | $124.88 | 2019 | |
| Emd Serono, INC. | $124.46 | 2024 | |
| Myovant Sciences INC. | $115.40 | 2021 | |
| Teleflex LLC | $111.85 | 2024 | |
| Aveo Pharmaceuticals, INC. | $108.84 | 2024 | |
| Pfizer INC. | $85.43 | 2024-2025 | |
| Stemline Therapeutics INC. | $75.71 | 2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $67.69 | 2022-2023 | Monoferric |
| Alexion Pharmaceuticals, INC. | $63.30 | 2023-2025 | Ultomiris |
| Amgen INC. | $60.27 | 2020-2023 | Xgeva |
| Sobi, INC | $52.56 | 2023-2024 | |
| Gilead Sciences, INC. | $49.53 | 2023-2024 | |
| Lilly USA, LLC | $40.39 | 2022 | |
| Array Biopharma INC | $37.85 | 2024 | Braftovi, Lorbrena, Mektovi |
| G1 Therapeutics, INC. | $29.42 | 2022 | |
| Pharmaand Gmbh | $28.89 | 2025 | Rubraca |
| Apellis Pharmaceuticals, INC. | $24.84 | 2023 | Empaveli |
| Recordati_rare_diseases_inc. | $23.68 | 2025 | Enjaymo |
| Tolmar Pharmaceuticals, INC. | $22.10 | 2019 | |
| Geron Corporation | $21.69 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $18.98 | 2023 | Qinlock |
| Tolmar, INC. | $17.91 | 2025 | Eligard, Rubraca |
| Sumitomo Pharma America, INC. | $17.80 | 2024 | Orgovyx |
| Biocon Biologics INC | $16.94 | 2024 | Ogivri |
| Amneal Pharmaceuticals LLC | $16.91 | 2023 | Neulasta, Neupogen, Avastin |
| Puma Biotechnology, INC. | $15.99 | 2022 | |
| West Therapeutics Development, LLC | $15.73 | 2020 | |
| Fortovia Therapeutics, INC. | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Panarese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.